| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2003PNAS..100..259L |
| P356 | DOI | 10.1073/PNAS.0235361100 |
| P932 | PMC publication ID | 140945 |
| P698 | PubMed publication ID | 12506199 |
| P5875 | ResearchGate publication ID | 10970098 |
| P50 | author | Yonghong Li | Q63912828 |
| P2093 | author name string | Hui Wang | |
| Su Wang | |||
| Barbara Cordell | |||
| Diana Quon | |||
| Yu-Wang Liu | |||
| P2860 | cites work | Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway | Q22009414 |
| Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE | Q22010705 | ||
| Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity | Q22010912 | ||
| Purification and cloning of amyloid precursor protein beta-secretase from human brain | Q22010914 | ||
| Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism | Q24309753 | ||
| A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex | Q24310068 | ||
| APP-BP1, a novel protein that binds to the carboxyl-terminal region of the amyloid precursor protein | Q24310276 | ||
| A new NEDD8-ligating system for cullin-4A | Q24321773 | ||
| Construction and characterization of a normalized cDNA library | Q24563649 | ||
| Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein | Q24650599 | ||
| Covalent modification of the homeodomain-interacting protein kinase 2 (HIPK2) by the ubiquitin-like protein SUMO-1 | Q24656539 | ||
| BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein | Q24675964 | ||
| Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. | Q27863703 | ||
| Cell cycle-regulated attachment of the ubiquitin-related protein SUMO to the yeast septins | Q27936336 | ||
| Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease | Q28140038 | ||
| Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3 | Q28145507 | ||
| An E3-like factor that promotes SUMO conjugation to the yeast septins | Q28188846 | ||
| SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation | Q28282094 | ||
| Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP | Q28592685 | ||
| The nuclear dot protein sp100, characterization of domains necessary for dimerization, subcellular localization, and modification by small ubiquitin-like modifiers | Q28616490 | ||
| Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase | Q29042710 | ||
| Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice | Q30764264 | ||
| Translating cell biology into therapeutic advances in Alzheimer's disease | Q33678168 | ||
| Processing of Alzheimer beta/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation | Q33731523 | ||
| Covalent modification of the transactivator protein IE2-p86 of human cytomegalovirus by conjugation to the ubiquitin-homologous proteins SUMO-1 and hSMT3b | Q33799527 | ||
| Ubiquitin-like proteins: new wines in new bottles | Q33901542 | ||
| SUMO, ubiquitin's mysterious cousin | Q33939449 | ||
| SP-RING for SUMO: new functions bloom for a ubiquitin-like protein | Q34094595 | ||
| The Role of presenilins in gamma-secretase activity | Q34116345 | ||
| Ubiquitin enters the new millennium | Q34388963 | ||
| Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor | Q34475374 | ||
| Conjugation of Nedd8 to CUL1 enhances the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization | Q45345753 | ||
| The ubiquitin pathway in Parkinson's disease | Q48015939 | ||
| Presenilins and the intramembrane proteolysis of proteins: facts and fiction. | Q53244411 | ||
| ??? | Q22251293 | ||
| P2507 | corrigendum / erratum | Correction | Q118228499 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | protein sumoylation | Q3503705 |
| P304 | page(s) | 259-264 | |
| P577 | publication date | 2002-12-27 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Positive and negative regulation of APP amyloidogenesis by sumoylation | |
| P478 | volume | 100 |
| Q57942267 | A Proteomic Strategy for Gaining Insights into Protein Sumoylation in Yeast |
| Q26798983 | A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome |
| Q47102504 | A genetic screen to discover SUMOylated proteins in living mammalian cells. |
| Q35209208 | A new wrestler in the battle between alpha- and beta-secretases for cleavage of APP. |
| Q42674921 | APP-BP1 inhibits Abeta42 levels by interacting with Presenilin-1. |
| Q37700238 | Age-related changes of protein SUMOylation balance in the AβPP Tg2576 mouse model of Alzheimer's disease |
| Q36932117 | Alterations in immunological and neurological gene expression patterns in Alzheimer's disease tissues |
| Q37106942 | Alzheimer's and non-alzheimer's dementia: a critical review of pharmacological and nonpharmacological strategies |
| Q24519076 | Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors |
| Q38557970 | Battling Alzheimer's Disease: Targeting SUMOylation-Mediated Pathways |
| Q45111727 | Cathepsin E generates a sumoylated intracellular fragment of the cell adhesion molecule L1 to promote neuronal and Schwann cell migration as well as myelination |
| Q44156118 | Characterization of SENP7, a SUMO-2/3-specific isopeptidase |
| Q42644852 | Combined Analysis of Phenotypic and Target-Based Screening in Assay Networks. |
| Q36401406 | Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease |
| Q38865366 | Dementia in Down's syndrome |
| Q27313862 | Disruption of SUMO-specific protease 2 induces mitochondria mediated neurodegeneration |
| Q35207883 | Drug discovery in the ubiquitin regulatory pathway |
| Q36995104 | Emerging extranuclear roles of protein SUMOylation in neuronal function and dysfunction |
| Q37741012 | Epigenetic regulation of HDAC1 SUMOylation as an endogenous neuroprotection against Aβ toxicity in a mouse model of Alzheimer's disease |
| Q56769911 | Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants |
| Q34477461 | Genetic Evidence That Polysumoylation Bypasses the Need for a SUMO-Targeted Ub Ligase |
| Q28275898 | Genetic and functional evidence supporting SUMO4 as a type 1 diabetes susceptibility gene |
| Q34674349 | Genome-wide miR-155 and miR-802 target gene identification in the hippocampus of Ts65Dn Down syndrome mouse model by miRNA sponges |
| Q52882876 | Lamin A reassembly at the end of mitosis is regulated by its SUMO-interacting motif. |
| Q40161850 | Modulation of Abeta generation by small ubiquitin-like modifiers does not require conjugation to target proteins |
| Q41962082 | Modulation of inducible nitric oxide synthase expression by sumoylation |
| Q38931172 | Mouse models of Down syndrome: gene content and consequences |
| Q36060432 | Multisite protein modification and intramolecular signaling |
| Q34295237 | Neuronal SUMOylation: mechanisms, physiology, and roles in neuronal dysfunction |
| Q49104487 | Neuronal and nonneuronal quantitative BACE immunocytochemical expression in the entorhinohippocampal and frontal regions in Alzheimer's disease |
| Q29903594 | Nuclear and unclear functions of SUMO |
| Q30422188 | Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations |
| Q35223610 | Profiles of SUMO and ubiquitin conjugation in an Alzheimer's disease model |
| Q40405262 | Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities |
| Q35085788 | Proteasome inhibition induces α-synuclein SUMOylation and aggregate formation |
| Q37553976 | Protein SUMOylation in neuropathological conditions. |
| Q38125942 | Protein sumoylation in brain development, neuronal morphology and spinogenesis. |
| Q48260013 | Receptor tyrosine kinases positively regulate BACE activity and Amyloid-beta production through enhancing BACE internalization |
| Q34606349 | Regulation of synaptic plasticity and cognition by SUMO in normal physiology and Alzheimer's disease |
| Q54986544 | SENP1 and SENP2 regulate SUMOylation of amyloid precursor protein. |
| Q64245877 | SET SUMOylation promotes its cytoplasmic retention and induces tau pathology and cognitive impairments |
| Q37297379 | SUMO and Alzheimer's disease |
| Q38132691 | SUMO rules: regulatory concepts and their implication in neurologic functions. |
| Q28243200 | SUMO wrestling with type 1 diabetes |
| Q34008085 | SUMO4 and its role in type 1 diabetes pathogenesis |
| Q97884803 | SUMOylation and calcium signalling: potential roles in the brain and beyond |
| Q28572063 | SUMOylation attenuates sensitivity toward hypoxia- or desferroxamine-induced injury by modulating adaptive responses in salivary epithelial cells |
| Q36115749 | SUMOylation-disrupting WAS mutation converts WASp from a transcriptional activator to a repressor of NF-κB response genes in T cells |
| Q26783370 | SUMOylation: Novel Neuroprotective Approach for Alzheimer's Disease? |
| Q24682911 | SUSP1 antagonizes formation of highly SUMO2/3-conjugated species |
| Q27652201 | Structure of the Human SENP7 Catalytic Domain and Poly-SUMO Deconjugation Activities for SENP6 and SENP7 |
| Q37413787 | Sumoylation and human disease pathogenesis |
| Q26747536 | Sumoylation in Synaptic Function and Dysfunction |
| Q38046126 | Sumoylation in neurodegenerative diseases |
| Q40002714 | Sumoylation is critical for DJ-1 to repress p53 transcriptional activity. |
| Q41150904 | Sumoylation of amyloid precursor protein negatively regulates Abeta aggregate levels |
| Q47799714 | Sumoylation: Implications for Neurodegenerative Diseases |
| Q36318546 | Targeting Ubc9 for cancer therapy |
| Q37728628 | Targets and consequences of protein SUMOylation in neurons. |
| Q44564184 | The SUMO isopeptidase Ulp2 prevents accumulation of SUMO chains in yeast |
| Q33821071 | The insect homologue of the amyloid precursor protein interacts with the heterotrimeric G protein Go alpha in an identified population of migratory neurons |
| Q28485287 | The proteome response to amyloid protein expression in vivo |
| Q38254163 | The role of ubiquitin and ubiquitin-like modification systems in papillomavirus biology |
| Q63432972 | Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP |
| Q38874015 | Ubiquitin-dependent and independent roles of SUMO in proteostasis |
| Q38047618 | WITHDRAWN: Protein sumoylation and human diseases |
| Q47953822 | mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia |
| Q118228499 | Correction | main subject | P921 |
Search more.